Download PDF
Aktuelle Urol 2000; 31(4): 212-228
DOI: 10.1055/s-2000-4654
ÜBERSICHT
Georg Thieme Verlag Stuttgart · New York

Molekulare Aspekte des Harnblasenkarzinoms Teil IIMolekulare Diagnostik des Harnblasenkarzinoms

Molecular Aspects of Bladder Carcinoma Part II. Molecular DiagnosticsI. Kausch, A. Böhle
  • Laborgruppe Immuntherapie, Forschungszentrum Borstel und Klinik für Urologie, Med. Universität Lübeck
Further Information

Publication History

Publication Date:
31 December 2000 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Obwohl das derzeitige Klassifikationssystem von Harnblasenkarzinomen durch Tumorstadium und -differenzierungsgrad nützliche Informationen leistet, kann der natürliche Verlauf der Erkrankung mit oder ohne Therapie nur eingeschränkt prognostiziert werden. Die Zystoskopie und Urinzytologie sind derzeit als Goldstandard in der Diagnostik und Überwachung des Harnblasenkarzinoms anzusehen. Die klassische Urinzytologie ist jedoch zumindest beim G1-Karzinom durch eine relativ niedrige Sensitivität gekennzeichnet und unterliegt einer deutlichen Untersucherabhängigkeit. Durch die Erforschung der molekularbiologischen Grundlagen von Karzinogenese und Tumorprogression wurde eine Vielzahl potentiell diagnostischer und prognostischer Marker für das Harnblasenkarzinom beschrieben. In der vorliegenden Übersichtsarbeit wurde die Literatur zu den verschiedenen Tumormarkern des Harnblasenkarzinoms im Hinblick auf deren prognostische und diagnostische Wertigkeit aktuell und umfassend dargestellt.

Schlussfolgerung: Unter der Prämisse, dass die Zystoskopie selbst nie evaluiert wurde, besteht derzeit kein diagnostischer Marker, der eine vergleichbare Sensitivität und Spezifität wie die Zystoskopie besitzt und diese ersetzen könnte. Unter den diagnostischen Markern scheint der kombinierte Nachweis mehrerer Tumorantigene, z. B. dem Immunocyt-Test, am vielversprechendsten zu sein. Solche vergleichsweise hoch sensitiven Testsysteme können möglicherweise in Zukunft die Zystoskopie bei der Nachsorge selektierter Patienten ersetzen oder Zystoskopieintervalle verlängern. Nach dem derzeitigen Stand scheint auch bei den prognostischen Markern die Kombination verschiedener Faktoren am ehesten in der Lage zu sein vorherzusagen, welche oberflächlichen Tumoren einer aggressiven Therapie und welche invasiven Tumoren einer adjuvanten Therapie bedürfen. Vielversprechend sind insgesamt die Daten zur Ki-67- und p53-Expression, dem Matrixmetalloproteinasenkomplex und der Angiogenese.

Abstract

The current system of classifying bladder carcinoma by stage and histological grade is very useful, yet still has limited ability to predict the natural history or treated natural history of a bladder tumor. Cystoscopy and urine cytology are currently considered the “gold standard” in the diagnosis and follow-up of bladder cancer. Classical urine cytology, however, at least in the diagnosis of G1-tumor, is characterized by a relatively low sensitivity. In the last few years, investigation of the basic mechanisms involved in carcinogenesis and tumor progression by molecular biology has provided a host of markers which are of potential diagnostic or prognostic value for bladder carcinoma. We provide a current, comprehensive review of the literature on bladder tumor markers and summerize their diagnostic and prognostic potential.

Conclusions: Under the premise that cystoscopy has never been subjected to evaluation, no diagnostic marker currently exists with a sensitivity and specificity comparable to cystoscopy. The combined analysis of several tumor markers as in the Immunocyt test seems to be the most promising approach. In the future these rather highly sensitive tests could replace cystoscopy or prolong the intervals between cystoscopies in the follow-up of selected patients. The literature suggests that no single marker is currently able to accurately predict the course of bladder tumors. A combination of prognostic markers could predict which superficial tumors need an aggressive form of therapy and which invasive tumors require adjuvant therapy. Altogether, the most promising markers are, at this point, Ki-67 and p53 expression as well as matrixmetalloproteinase complex and angiogenesis.

Key words:

Bladder neoplasms - Tumor markers, biological - Biology, molecular - Urinalysis - Indicators - Prognosis

Literatur

  • 1 Stein J P, Grossfeld G D, Ginsberg D A, Esrig D, Freeman J A, Figueroa A J, Skinner D G, Cote R J. Prognostic markers in bladder cancer: a contemporary review of the literature.  J Urol. 1998;  160 (3 Pt 1) 645-659
    PubMedGoogle Scholar
  • 2 Böhle A, Jocham D. Die intravesikale Immuntherapie mit Bacillus Calmette-Guérin. Fakten, Vergleiche, Ergebnisse. Stuttgart, Jena, Lübeck, Ulm: Gustav Fischer Verlag 1998
    Google Scholar
  • 3 Herr H W. Tumor progression and survival of patients with high grade, noninvasive papillary (TaG3) bladder tumors: 15-year outcome.  J Urol. 2000;  163 (1) 60-62
    CrossrefPubMedGoogle Scholar
  • 4 Pirtskalaishvili G, Konety B R, Getzenberg R H. Update on urine-based markers for bladder cancer. How sensitive and specific are the new noninvasive tests.  Postgrad Med. 1999;  106 (6) 85-86 91-94
    PubMedGoogle Scholar
  • 5 Koss L G. Diagnostic cytology of the urinary tract - with histopathologic and clinical correlations. Lippincott-Raven 1995
    Google Scholar
  • 6 Dalbagni G, Reuter V E, Sheinfeld J, Fradet Y, Fair W R, Cordon-Cardo C. Cell surface differentiation antigens of normal urothelium and bladder tumors.  Sem Surg Oncol. 1992;  8 293-299
    PubMedGoogle Scholar
  • 7 Fradet Y, Cordon-Cardo C. Critical appraisal of tumor markers in bladder cancer.  Sem Urol. 1993;  11 145-153
    PubMedGoogle Scholar
  • 8 Bonner R B, Hemstreet G P, Fradet Y, Rao J Y, Min K W, Hurst R E. Bladder cancer risk assessment with quantitative fluorescence image analysis of tumor markers in exfoliated bladder cells.  Cancer. 1993;  72 (8) 2461-2469
    PubMedGoogle Scholar
  • 9 Fradet Y, Tardif M, Bourget L, Robert J. Clinical cancer progression in urinary bladder tumors evaluated by multiparameter flow cytometry with monoclonal antibodies. Laval University Urology Group.  Cancer Res. 1990;  50 (2) 432-437
    PubMedGoogle Scholar
  • 10 Fradet Y. Phenotypic characterization of bladder cancer.  Eur Urol. 1998;  33 (Suppl. 4) 5-6
    CrossrefPubMedGoogle Scholar
  • 11 Bretton P, Cordon-Cardo C, Wartinger D, Kimmel M, Fair W R, Melamed M R, Fradet Y. Proc Amer Assn Cancer Res. 1990;  31 186 abstract 105
    PubMed
  • 12 Sarosdy M F, Hudson M A, Ellis W J, Soloway M S. Improved detection of recurrent bladder cancer using the Bard BTA stat Test.  Urology. 1997;  50 349-353
    CrossrefPubMedGoogle Scholar
  • 13 D'Hallewin M A, Baert L. Initial evaluation of the bladder tumor antigen test in superficial bladder cancer.  J Urol. 1996;  155 (2) 475-476
    PubMedGoogle Scholar
  • 14 Takashi M, Schenck U, Kissel K, Leyh H, Treiber U. Use of diagnostic categories in urinary cytology in comparison with the bladder tumour antigen (BTA) test in bladder cancer patients.  Int Urol Nephrol. 1999;  31 (2) 189-196
    CrossrefPubMedGoogle Scholar
  • 15 Landman J, Chang Y, Kavaler E, Droller M J, Liu B C. Sensitivity and specificity of NMP-22, telomerase, and BTA in the detection of human bladder cancer.  Urology. 1998;  52 (3) 398-402
    CrossrefPubMedGoogle Scholar
  • 16 Murphy W M, Rivera-Ramirez I, Medina C A, Wright N J, Wajsman Z. The bladder tumor antigen (BTA) test compared to voided urine cytology in the detection of bladder neoplasms.  J Urol. 1997;  158 2102-2106
    PubMedGoogle Scholar
  • 17 Ellis J W, Blumenstein B A, Ishak L M, Enfield D L. Clinical evaluation of the BTA TRAK assay and comparison to voided urine cytology and the Bard BTA test in patients with recurrent bladder tumors.  The Multi Center Study Group Urology. 1997;  50 882-887
    PubMedGoogle Scholar
  • 18 Pode D, Shapiro A, Wald M, Nativ O, Laufer M, Kaver I. Noninvasive detection of bladder cancer with the BTA STAT test.  J Urol. 1999;  161 (2) 443-446
    PubMedGoogle Scholar
  • 19 Ramakumar S, Bhuiyan J, Besse J A, Steven G R, Wollan P C, Blute M L, O'Kane D J. Comparison of screening methods in the detection of bladder cancer.  J Urol. 1999;  161 (2) 388-394
    PubMedGoogle Scholar
  • 20 Leyh H, Hall R, Mazemann E. Wertigkeit von BTA-Test und Urinzytologie bei der Diagnostik und Nachsorge des Harnblasenkarzinoms.  Akt Urol. 1998;  29 57-61
    PubMedGoogle Scholar
  • 21 Nunez C, Martinez-Pineiro L, Madrid F J, Cisnero J, Viguer J W, Martinez-Pineiro J A. Die Wertigkeit des BTA-Tests zur Erkennung des Blasenkarzinoms.  Akt Urol. 1999;  30 112-117
    Article in Thieme ConnectPubMedGoogle Scholar
  • 22 Mahnert B, Tauber S, Kriegmair M. et al . BTA-TRAK - a useful diagnostic tool in urinary bladder cancer.  Anticancer Res. 1999;  19 2615-2619
    PubMedGoogle Scholar
  • 23 Mian C, Pycha A, Wiener H, Haitel A, Lodde M, Marberger M. Immunocyt: a new tool for detecting transitional cell cancer of the urinary tract.  J Urol. 1999;  161 (5) 1486-1489
    PubMedGoogle Scholar
  • 24 Getzenberg R H, Konety B R, Oeler T A, Quigley M M, Hakam A, Becich M J, Bahnson R R. Bladder cancer-associated nuclear matrix proteins.  Cancer Res. 1996;  56 (7) 1690-1694
    PubMedGoogle Scholar
  • 25 Wiener H G, Mian C, Haitel A, Pycha A, Schatzl G, Marberger M. Can urine bound diagnostic tests replace cystoscopy in the management of bladder cancer.  J Urol. 1998;  159 1876-1880
    PubMedGoogle Scholar
  • 26 Stampfer D S, Carpinito G A, Rodriguez-Villanueva J, Willsey L W, Dinney C P, Grossman H B, Fritsche H A, McDougal W S. Evaluation of NMP22 in the detection of transitional cell carcinoma of the bladder.  J Urol. 1998;  159 (2) 394-398
    PubMedGoogle Scholar
  • 27 Soloway M S, Briggman V, Carpinito G A, Chodak G W, Church P A, Lamm D L, Lange P, Messing E. Use of a new tumor marker, urinary NMP22, in the detectio of occult or rapidly recurring transitional cell carcinoma of the urinary tract following surgical treatment.  J Urol. 1996;  156 (2 Pt1) 363-367
    PubMedGoogle Scholar
  • 28 Waldner M, Ubrig B, Roth S. Screening und Nachsorge des Urothelkarzinoms - Welchen Stellenwert haben Tumormarker.  Urologe B. 1999;  39 321-324
    CrossrefPubMedGoogle Scholar
  • 29 Sanchez-Carbayo M, Herrero E, Megias J, Mira A, Soria F. Comparative sensitivity of urinary CYFRA 21-1, urinary bladder cancer antigen, tissue polypeptide antigen, tissue polypeptide antigen and NMP22 to detect bladder cancer.  J Urol. 1999;  162 (6) 1951-1956
    PubMedGoogle Scholar
  • 30 Zippe C, Pandrangi L, Agarwal A. NMP22 is a sensitive, cost-effective test in patients at risk for bladder cancer.  J Urol. 1999;  161 62-65
    PubMedGoogle Scholar
  • 31 Poulakis V, Witzsch U, Kollias A, Wolfram M, Becht E, Altmannsberger H M. Vergleich des NMP22TM- und BTA-statTM-Tests mit der Urinzytologie und Zystoskopie in der Diagnose und Nachsorge des Blasenkarzinoms: Können die NMP22TM- und BTA-statTM-Tests die Zystoskopie ersetzen.  Akt Urol. 1999;  30 466-475
    PubMedGoogle Scholar
  • 32 Sheinfeld J, Reuter V E, Melamed M R, Fair W R, Morse M. Enhanced bladder cancer detection with the Lewis X antigen as a marker of neoplastic transformation.  J Urol. 1990;  143 285-288
    PubMedGoogle Scholar
  • 33 Planz B, Striepecke E, Jakse G, Bocking A. Use of Lewis X antigen and deoxyribonucleic acid image cytometry to increase sensitivity of urinary cytology in transitional cell carcinoma of the bladder.  J Urol. 1998;  159 (2) 384-388
    PubMedGoogle Scholar
  • 34 Golijanin D, Sherman Y, Shapiro A, Pode D. Detection of bladder tumors by immunostaining of the Lewis X antigen in cells from voided urine.  Urology. 1995;  46 (2) 173-177
    CrossrefPubMedGoogle Scholar
  • 35 Pode D, Golijanin D, Sherman Y, Lebensart P, Shapiro A. Immunostaining of Lewis X in cells from voided urine, cytopathology and ultrasound for noninvasive detection of bladder tumors.  J Urol. 1998;  159 (2) 389-393
    PubMedGoogle Scholar
  • 36 Wajsman Z, Merrin C E, Chu T M, Moore R H, Murphy G P. Evaluation of biological markers in bladder cancer.  J Urol. 1975;  114 (6) 879-893
    PubMedGoogle Scholar
  • 37 Schmetter B S, Habicht K K, Lamm D L, Morales A, Bander N H, Grossman H B, Hanna M G Jr, Silberman S R. A multicenter trial evaluation of the fibrin/fibrinogen degradation products test for detection and monitoring of bladder cancer.  J Urol. 1997;  157 (3 pt 1) 801-805
    PubMedGoogle Scholar
  • 38 Johnston B, Morales A, Emerson L, Lundie M. Rapid detection of bladder cancer: a comparative study of point of care tests.  J Urol. 1997;  158 (6) 2098-2101
    PubMedGoogle Scholar
  • 39 Kyo S, Kunimi K, Uchibayashi T, Namiki M, Inoue M. Telomerase activity in human urothelial tumors.  Am J Clin Pathol. 1997;  107 (5) 555-560
    PubMedGoogle Scholar
  • 40 Kinoshita H, Ogawa O, Kakehi Y, Mishina M, Mitsumori K, Itoh N, Yamada H, Terachi T. Detection of telomerase activity in exfoliated cells in urine from patients with bladder cancer.  J Natl Cancer Inst. 1997;  89 (10) 724-730
    CrossrefPubMedGoogle Scholar
  • 41 Yoshida K, Sugino T, Tahara H, Woodman A, Bolodeoku J, Nargund V, Fellows G, Goodison S. Telomerase activity in bladder carcinoma and its implicatio for noninvasive diagnosis by detection of exfoliated cancer cells in urine.  Cancer. 1997;  79 (2) 362-369
    CrossrefPubMedGoogle Scholar
  • 42 Liebert M, Gebhardt D, Wood C, Chen I L, Ellard J, Amancio D, Grossman H B. Urothelial differentiation and bladder cancer.  Adv Exp Med Biol. 1999;  462 437-448
    PubMedGoogle Scholar
  • 43 Rao J Y, Hemstreet G P3, Hurst R E, Bonner R B, Jones P L, Min K W, Fradet Y. Alterations in phenotypic biochemical markers in bladder epithelium during tumorigenesis.  Proc Nat Acad Sci. 1993;  90 (17) 8287-8291
    PubMedGoogle Scholar
  • 44 Hemstreet G P3, Rao J, Hurst R E, Bonner R B, Waliszewski P, Grossman H B, Liebert M, Bane B L. G-actin as a risk factor and modulatable endpoint for cancer chemoprevention trials.  J Cell Biochem Suppl. 1996;  25 197-204
    PubMedGoogle Scholar
  • 45 Tanaka M, Mullauer L, Ogiso Y, Fujita H, Moriya S, Furuuchi K, Harabayashi T, Shinohara N. Gelsolin: a candidate for suppressor of human bladder cancer.  Cancer Res. 1995;  55 (15) 3228-3232
    PubMedGoogle Scholar
  • 46 Southgate J, Harnden P, Trejdosiewicz L K. Cytokeratin expression patterns in normal and malignant urothelium: a review of the biological and diagnostic implications.  Histol Histopathol. 1999;  14 (2) 657-664
    PubMedGoogle Scholar
  • 47 Moll R, Achtstatter T, Brecht E, Balcarova-Stander J, Ittensohn M, Franke W W. Cytokeratins in normal and malignant transitional epithelium. Maintenance of expression of urothelial differentiation features in transitional cell carcinomas and bladder carcinoma cell culture lines.  Am J Pathol. 1988;  132 (1) 123-144
    PubMedGoogle Scholar
  • 48 Moll R, Lowe A, Laufer J, Franke W W. Cytokeratin 20 in human carcinomas. A new histodiagnostic marker detected by monoclonal antibodies.  Am J Path. 1992;  140 (2) 427-447
    PubMedGoogle Scholar
  • 49 Stieber P, Schmeller N, Schambeck C, Hofmann K, Reiter W, Hasholzner U, Fateh-Moghadam A. Clinical relevance of CYFRA 21-1, TPA-IRMA and TPA-LIA-mat in urinary bladder cancer.  Anticancer Res. 1996;  16 (6 B) 3793-3798
    PubMedGoogle Scholar
  • 50 Maulard-Durdux C, Toubert M E, Hennequin C, Housset M. Serum tissue polypeptide antigen in bladder cancer as a tumor marker: a prospective study.  J Clin Oncol. 1997;  15 (12) 3446-3450
    PubMedGoogle Scholar
  • 51 Yao W J, Chang C J, Chan S H, Chow N H, Cheng H L, Tzai T S, Lin S N. Significance of urinary tissue polypeptide specific antigen (TPS) determination in patients with urothelial carcinoma.  Anticancer Res. 1995;  15 (6 B) 2819-2823
    PubMedGoogle Scholar
  • 52 Sánchez-Carbayo M, Herrero E, Megias J, Mira A, Soria F. Comparative sensitivity of urinary CYFRA 21-1, urinary bladder cancer antigen, tissue polypeptide antigen, tissue polypeptide antigen and NMP22 to detect bladder cancer.  J Urol. 1999;  162 (6) 1951-1956
    PubMedGoogle Scholar
  • 53 Pariente J L, Bordenave L, Michel P, Latapie M J, Ducassou D, Le Guillou M. Initial evaluation of CYFRA 21-1 diagnostic performances and a urinary marker in bladder transitional cell carcinoma.  J Urol. 1997;  158 (2) 338-341
    PubMedGoogle Scholar
  • 54 Koss L G. The asymmetric unit membranes of the epithelium of the urinary bladder of the rat. An electron microscopic study of a mechanism of epithelial maturation and function.  Lab Invest. 1969;  21 (2) 154-168
    PubMedGoogle Scholar
  • 55 Wu X R, Manabe M, Yu J, Sun T T. Large scale purification and immunolocalization of bovine uroplakins I, II and III. Molecular markers of urothelial differentiation.  J Biol Chem. 1990;  265 (31) 19170-19179
    PubMedGoogle Scholar
  • 56 Moll R, Wu X R, Lin J H, Sun T T. Uroplakins, specific membrane proteins of urothelial umbrella cells, as histological markers of metastatic transitional cell carcinomas.  Am J Path. 1995;  147 (5) 1383-1397
    PubMedGoogle Scholar
  • 57 Ravery V, Colombel M, Popov Z, Bastuji S, Patard J J, Bellot J, Abbou C, Fradet Y. Prognostic value of epidermal growth factor-receptor, T138 and T43 expression in bladder cancer.  Br J Cancer. 1995;  71 (1) 196-200
    PubMedGoogle Scholar
  • 58 Lloyd K O. Philip Levine award lecture. Blood group antigens as markers for normal differentiation and malignant change in human tissues.  Am J Clin Pathol. 1987;  87 (1) 129-139
    PubMedGoogle Scholar
  • 59 Newman A J Jr, Carlton C E Jr, Johnson S. Cell surface A, B or 0(H) blood group antigens as an indicator of malignant potential in stage A bladder carcinoma.  J Urol. 1980;  124 (1) 27-29
    PubMedGoogle Scholar
  • 60 Weinstein R S, Alroy J, Farrow G M, Miller A W, Davidsohn I. Blood group isoantigen deletion in carcinoma in situ of the urinary bladder.  Cancer. 1979;  43 (2) 661-668
    PubMedGoogle Scholar
  • 61 Cordon-Cardo C, Reuter V E, Lloyd K O, Sheinfeld J, Fair W R, Old L J, Melamed M R. Blood group-related antigens in human urothelium: enhanced expression of precursers, LeX and LeY determinants in urothelial carcinoma.  Cancer Res. 1988;  48 4113-4120
    PubMedGoogle Scholar
  • 62 Brandau S, Böhle A. Molekulare und genetische Mechanismen bei der Entstehung des Harnblasenkarzinoms.  Akt Urol. 2000;  in Press
    PubMedGoogle Scholar
  • 63 Fontana D, Bellina M, Scoffone C, Cagnazzi E, Cappia S, Cavallo F, Russo R, Leonardo D. Evaluation of c-ras oncogene product (p21) in superficial bladder cancer.  Eur Urol. 1996;  29 470-476
    PubMedGoogle Scholar
  • 64 Kotake T, Saiki S, Kinouchi T, Shiku H, Nakayama E. Detection of c-myc gene product in urinary bladder cancer.  Jap J Cancer Res. 1990;  81 1198-1201
    PubMedGoogle Scholar
  • 65 Lipponen P K. Expression of c-myc protein is related to cell proliferation and expression of growth factor receptors in transitional call bladder cancer.  J Path. 1995;  175 203-210
    PubMedGoogle Scholar
  • 66 Moriyama M, Akiyama T, Yamamoto T, Kawamoto T. Expression of c-erb-2 gene product in urinary bladder cancer.  J Urol. 1991;  145 423-427
    PubMedGoogle Scholar
  • 67 Sato K, Moriyama M, Mori S, Saito M. An immunohistologic evaluation of c-erbB-2 gene product in patients with urinary bladder carcinoma.  Cancer. 1992;  70 2493-2498
    PubMedGoogle Scholar
  • 68 Mellon J K, Lunec J, Wright C, Horne C H, Kelly P, Neal D E. C-erbB-2 in bladder cancer: molecular biology, correlation with epidermal growth factor receptors and prognostic value.  J Urol. 1996;  155 (1) 321-326
    PubMedGoogle Scholar
  • 69 Underwood M, Bartlett J, Reeves J, Gardiner D S, Scott R, Cooke T. C-erbB-2 gene amplification: a molecular marker in recurrent bladder tumors.  Cancer Res. 1995;  55 (11) 2422-2430
    PubMedGoogle Scholar
  • 70 Habuchi T, Konoshita H, Yamada H, Kakegi Y, Ogawa O, Wu W J, Takahashi R, Sugiyama T. Oncogene amplification in urothelial cancers with p53 gene mutation or MDM2 amplification.  J Natl Cancer Inst. 1994;  86 1331-1335
    PubMedGoogle Scholar
  • 71 Lianes P, Orlow I, Zhang Z F, Oliva M R, Sarkis A S, Reuter V E, Cordon-Cardo C. Altered patterns of MDM2 and TP53 expression in human bladder cancer.  J Natl Cancer Inst. 1994;  86 (17) 1325-1330
    PubMedGoogle Scholar
  • 72 Shiina H, Igawa M, Nagami H, Yagi H, Urakami S. Immunohistochemical analysis of proliferating cell nuclear antigen, p53 protein and nm23 protein and nuclear DNA content in transitional cell carcinoma of the bladder.  Cancer. 1996;  78 1762-1774
    CrossrefPubMedGoogle Scholar
  • 73 Bagchi S, Weinmann R, Raychaudhuri P. The retinoblastoma protein copurifes with E2F-I, an E1A-regulated inhibitor of the transcription factor E2F.  Cell. 1991;  65 (6) 1063-1072
    CrossrefPubMedGoogle Scholar
  • 74 Xu H M, Cairns P, Hu S X, Knowles M A, Benedict W F. Loss of RB protein expression in primary bladder cancer correlates with loss of heterozygosity at the RB locus and tumor progression.  Int J Cancer. 1993;  53 781-784
    PubMedGoogle Scholar
  • 75 Cordon-Cardo C, Wartinger D, Petrylak D, Dalbagni G, Fair W R, Fuks Z, Reuter V E. Altered expression of the retinoblastoma gene product: prognostic indicator in bladder cancer.  J Natl Cancer Inst. 1992;  84 1251-1256
    PubMedGoogle Scholar
  • 76 Logothetis C J, Xu H R, Ro J Y, Hu S X, Sahin A, Ordonez N, Benedict W F. Altered expression of retinoblastoma protein and known prognostic variables in locally advanced bladder cancer.  J Natl Cancer Inst. 1992;  84 (16) 1256-1261
    PubMedGoogle Scholar
  • 77 Grossman H B, Liebert M, Antelo M, Dinney C P, Hu S X, Palmer J L, Benedict W F. p53 and RB expression predict progression in T1 bladder cancer.  Clin Cancer Res. 1998;  4 (4) 829-834
    PubMedGoogle Scholar
  • 78 Hollstein M, Sidransky D, Vogelstein B, Harris C C. p53 mutations in human cancers.  Science. 1991;  253 49-53
    CrossrefPubMedGoogle Scholar
  • 79 Esrig D, Spruck C H, Nichols P W, Chaiwun B, Groshen S, Chen S C, Skinner D G, Jones P A. p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade and stage in bladder cancer.  Amer J Pathol. 1993;  143 1389-1397
    PubMedGoogle Scholar
  • 80 Pfister C, Buzelin F, Casse C, Bochereau G, Buzelin J M, Bouchot O. Comparative analysis of MiB1 and p53 expression in human bladder tumors and their correlation with cancer progression.  Eur Urol. 1998;  33 (3) 278-284
    CrossrefPubMedGoogle Scholar
  • 81 Esrig D, Elmajian D, Groshen S, Freeman J A, Stein J P. Accumulation of nuclear p53 and tumor progression in bladder cancer.  New Engl J Med. 1994;  331 1259-1264
    CrossrefPubMedGoogle Scholar
  • 82 Sarkis A, Bajorin D F, Reuter V E, Herr H W. Prognostic value of p53 nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant MVAC.  J Clin Oncol. 1995;  13 1384-1390
    PubMedGoogle Scholar
  • 83 Lipponen P K. Over-expression of p53 nuclear oncoprotein in traditional-cell bladder cancer and its prognostic value.  Int J Cancer. 1993;  53 (3) 365-370
    PubMedGoogle Scholar
  • 84 Pfister C, Moore L, Allard P, LaRue H, Lacombe L, Tetu B, Meyer F, Fradet Y. Predictive value of cell cycle markers p53, MDM2, p21, and Ki67 in superficial bladder tumor recurrence.  Clin Cancer Res. 1999;  5 (12) 4079-4084
    PubMedGoogle Scholar
  • 85 Phillips H A, Howard G C, Miller W R. P53 mutations as a marker of malignancy in bladder washing samples from patients with bladder cancer.  Br J Cancer. 2000;  82 (1) 136-141
    CrossrefPubMedGoogle Scholar
  • 86 Stein J P, Ginsberg D A, Grossfeld G D, Chatterjee S J, Esrig D, Dickinson M G, Groshen S, Taylor C R. Effect of p21WAF1/CIP1 expression on tumor progression in bladder cancer.  J Natl Cancer Inst. 1998;  90 (14) 1072-1079
    CrossrefPubMedGoogle Scholar
  • 87 Lipponen P, Aaltomaa S, Eskelinen M, Ala-Opas M, Kosma V M. Expression of p21 (waf1/cip1) protein in transitional cell bladder tumours and its prognostic value.  Eur Urol. 1998;  34 (3) 237-243
    CrossrefPubMedGoogle Scholar
  • 88 Cote R J, Esrig D, Groshen S, Jones P A, Skinner D G. p53 and treatment of bladder cancer.  Nature. 1997;  385 (6612) 123-125
    PubMedGoogle Scholar
  • 89 Waldman T, Lengauer C, Kinzler K W, Vogelstein B. Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21.  Nature. 1996;  381 (6584) 713-716
    CrossrefPubMedGoogle Scholar
  • 90 Gros P, Croop J, Housman D. Mammalian multidrug resistance gene: complete cDNA sequence indicates strong homology to bacterial transport proteins.  Cell. 1986;  47 (3) 371-380
    CrossrefPubMedGoogle Scholar
  • 91 Endicott J A, Ling V. The biochemistry of P-glycoprotein-mediated multidrug resistance.  Annu Rev Biochem. 1989;  58 137-171
    CrossrefPubMedGoogle Scholar
  • 92 Naito S, Sakamoto N, Kotoh S, Goto K, Matsumoto T, Kumazawa J. Correlation between the expression of P-glycoprotein and multidrug-resistant phenotype in transitional cell carcinoma of the urinary tract.  Eur Urol. 1992;  22 (2) 158-162
    PubMedGoogle Scholar
  • 93 Nakagawa M, Emoto A, Nasu N, Hanada T, Kuwano M, Cole S P, Nomura Y. Clinical significance of multi-drug resistance associated protein and P-glycoprotein in patients with bladder cancer.  J Urol. 1997;  157 (4) 1260-1264
    PubMedGoogle Scholar
  • 94 Gerdes J, Lemke H, Baisch H, Wacker H H, Schwab U, Stein H. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67.  J Immunol. 1984;  133 1710-1715
    PubMedGoogle Scholar
  • 95 Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown.  J Cell Physiol. 2000;  182 (3) 311-322
    CrossrefPubMedGoogle Scholar
  • 96 Cohen M B, Waldman F M, Carroll P R, Kerschmann R, Chew K, Mayall B H. Comparison of 5 histopathologic methods to assess cellular proliferation in transitional cell carcinoma of the urinary bladder.  Hum Path. 1993;  24 772-778
    PubMedGoogle Scholar
  • 97 Popov Z, Hoznek A, Colombel M, Bastuji-Garin S, Lefrere-Belda M A, Bellot J, Abbou C C, Mazerolles C. The prognostic value of p53 nuclear overexpression and MIB-1 as a proliferative marker in transitional cell carcinoma of the bladder.  Cancer. 1997;  80 1472-1481
    CrossrefPubMedGoogle Scholar
  • 98 Liukkonen T, Rajala P, Raitanen M, Rintala E, Kaasinen E, Lipponen P. Prognostic value of MIB-1 score, p53, EGFr, mitotic index and papillary status in primary superficial (stage pTa/T1) bladder cancer: a prospective comparative study.  Eur Urol. 1999;  36 393-400
    CrossrefPubMedGoogle Scholar
  • 99 Bravo R, Macdonald-Bravo H. Changes in the nuclear distribution of cyclin (PCNA) but not its synthesis depend on DNA replication.  EMBO J. 1985;  4 (3) 655-661
    PubMedGoogle Scholar
  • 100 Freeman A, Morris L S, Mills A D, Stoeber K, Laskey R A, Williams G H, Coleman N. Minichromosome maintenance proteins as biological markers of dysplasia and malignancy.  Clin Cancer Res. 1999;  5 (8 2121-2132
    PubMedGoogle Scholar
  • 101 Stoeber K, Halsall I, Freeman A, Swinn R, Doble A, Morris L, Coleman N, Bullock B. Immunoassay for urothelial cancers that detects DNA replication protein Mcm5 in urine.  The Lancet. 1999;  354 1524-1525
    CrossrefPubMedGoogle Scholar
  • 102 Folkman J, Klagsbrun M. Vascular physiology. A family of angiogenic peptides.  Nature. 1987;  329 (6141) 671-672
    CrossrefPubMedGoogle Scholar
  • 103 Bochner B H, Cote R J, Weidner N, Groshen S, Chen S C, Skinner D G, Nichols P W. Angiogenesis in bladder cancer: relationship between microvessel density and tumor prognosis.  J Natl Cancer Inst. 1995;  87 1603-1612
    PubMedGoogle Scholar
  • 104 Chaudhary R, Bromley M, Clarke N W, Betts C D, Barnard R J, Ryder W D, Kumar S. Prognostic relevance of micro-vessel density in cancer of the urinary bladder.  Anticancer Res. 1999;  19 (4 C) 3479-3484
    PubMedGoogle Scholar
  • 105 Philp E A, Stephenson T J, Reed M W. Prognostic significance of angiogenesis in transitional cell carcinoma of the human urinary bladder.  Br J Urol. 1996;  77 (3) 352-357
    PubMedGoogle Scholar
  • 106 Ozer E, Mungan M U, Tuna B, Kazimoglu H, Yorukoglu K, Kirkali Z. Prognostic significance of angiogenesis and immunoreactivity of cathepsin D and type IV collagen in high-grade stage T1 primary bladder cancer.  Urology. 1999;  54 (1) 50-55
    CrossrefPubMedGoogle Scholar
  • 107 Hawke C K, Delahunt B, Davidson P J. Microvessel density as a prognostic marker for transitional cell carcinoma of the bladder.  Br J Urol. 1998;  81 (4) 585-590
    PubMedGoogle Scholar
  • 108 Grossfeld G D, Ginsberg D A, Stein J P, Bochner B H, Esrig D, Groshen S, Dunn M, Nichols P W. Thrombospondin-1 expression in bladder cancer: association with p53 alterations, tumor angiogenesis, and tumor progression.  J Natl Cancer Inst. 1997;  89 (3) 219-227
    CrossrefPubMedGoogle Scholar
  • 109 Cohen M B, Griebling T L, Ahaghotu C A, Rokhlin O W, Ross J S. Cellular adhesion molecules in urologic malignancies.  Am J Clin Pathol. 1997;  107 (1) 56-63
    PubMedGoogle Scholar
  • 110 Birchmeier W. E-cadherin as a tumor (invasion) suppressor gene.  Bioessays. 1995;  17 (2) 97-99
    CrossrefPubMedGoogle Scholar
  • 111 Takeichi M. Cadherin cell adhesion receptors as a morphogenetic regulator.  Science. 1991;  251 (5000) 1451-1455
    CrossrefPubMedGoogle Scholar
  • 112 Ozawa M, Kemler R. Molecular organization of the uvomorulin-catenin complex.  J Cell Biol. 1992;  116 (4) 989-996
    CrossrefPubMedGoogle Scholar
  • 113 Bringuier P P, Umbas R, Schaafsma H E, Karthaus F M, Debruyne F M, Schalken J A. Decreased E-Cadherin immunoreactivity correlates with poor survival in patients with bladder tumors.  Cancer Res. 1993;  53 3241-3245
    PubMedGoogle Scholar
  • 114 Fujisawa M, Miyazaki J, Takechi Y, Arakawa S, Kamidono S. The significance of E-cadherin in transitional-cell carcinoma of the human urinary bladder.  World J Urol. 1996;  14 (suppl. 1) 12-15
    PubMedGoogle Scholar
  • 115 Otto T, Birchmeier W, Schmidt U, Hinke A, Schipper J, Rübben H, Raz A. Inverse relation of E-cadherin and autocrine motility factor receptor expression as a prognostic factor in patients with bladder carcinomas.  Cancer Res. 1994;  54 3120-3123
    PubMedGoogle Scholar
  • 116 Syrigos K N, Harrington K, Waxman J, Krausz T, Pignatelli M. Altered gamma-catenin expression correlates with poor survival in patients with bladder cancer.  J Urol. 1998;  160 (5) 1889-1893
    PubMedGoogle Scholar
  • 117 Lipponen P K, Eskelinen M J. Reduced expression of E-cadherin is related to invasive disease and frequent recurrence in bladder cancer.  J Cancer Res Clin Oncol. 1995;  54 303-308
    PubMedGoogle Scholar
  • 118 Shimazui T, Schalken J A, Giroldi L A, Jansen C F, Akaza H, Koiso K, Debruyne F M, Bringuier P P. Prognostic value of cadherin-associated molecules (alpha-, beta- and gamma catenins and p120cas) in bladder tumors.  Cancer Res. 1996;  56 4154-4158
    PubMedGoogle Scholar
  • 119 Griffiths T R, Brotherick I, Bishop R I, White M D, McKenna D M, Horne C H, Shenton B K, Neal D E. Cell adhesion molecules in bladder cancer: soluble serum E-cadherin correlates with predictors of recurrence.  Br J Cancer. 1996;  74 (4) 579-584
    PubMedGoogle Scholar
  • 120 Protheroe A S, Banks R E, Mzimba M, Porter W H, Southgate J, Singh P N, Bosomworth M, Harnden P. Urinary concentrations of the soluble adhesion molecule E-cadherin and total protein in patients with bladder cancer.  Br J Cancer. 1999;  80 (1 - 2) 273-278
    CrossrefPubMedGoogle Scholar
  • 121 Liebert M, Washington R, Wedemeyer G, Carey T E, Grossman H B. Loss of co-localization of alpha 6 beta 4 integrin and collagen VII in bladder cancer.  Am J Pathol. 1994;  144 (4) 787-795
    PubMedGoogle Scholar
  • 122 Grossman H B, Lee C, Bromberg J, Liebert M. Expression of the alpha6 beta4 integrin provides prognostic information in bladder cancer.  Oncol Rep. 2000;  7 (1) 13-16
    PubMedGoogle Scholar
  • 123 Liebert M, Washington R, Stein J, Wedemeyer G, Grossman H B. Expression of the VLA β1 integrin family in bladder cancer.  Am J Pathol. 1994;  144 1016-1022
    PubMedGoogle Scholar
  • 124 Chow N H, Cheng C J, Chi Y C, Liu H S, Tzai T S, Lin J S. Potential value of urinary intercellular adhesion molecule-1 determination in patients with bladder cancer.  Urology. 1998;  52 (6) 1015-1019
    CrossrefPubMedGoogle Scholar
  • 125 Campbell S C, Tanabe K, Alexander J P, Edinger M, Tubbs R R, Klein E A. Intercellular adhesion molecule-1 expression by bladder cancer cells: functional effects.  J Urol. 1994;  151 (5) 1385-1390
    PubMedGoogle Scholar
  • 126 Mungan U, Kirkali G, Celebi I, Kirkali Z. Significance of serum laminin P1 values in patients with transitional cell carcinoma of the bladder.  Urology. 1996;  48 496-500
    CrossrefPubMedGoogle Scholar
  • 127 Lipponen P K. Expression of cathepsin D in transitional cell bladder tumours.  J Pathol. 1996;  178 59-64
    PubMedGoogle Scholar
  • 128 Hasui Y, Marutsuka K, Asada Y, Osada Y. Prognostic value of urokinase-type plasminogen activator in patients with superficial bladder cancer.  Urology. 1996;  47 34-37
    CrossrefPubMedGoogle Scholar
  • 129 Ozdemir E, Kakehi Y, Okuno H, Yoshida O. Role of matrix metalloproteinase-9 in the basement membrane destruction of superficial urothelial carcinomas.  J Urol. 1999;  161 (4) 1359-1363
    PubMedGoogle Scholar
  • 130 Bianco F J Jr, Gervasi D C, Tiguert R, Grignon D J, Pontes J E, Crissman J D, Fridman R, Wood D P Jr. Matrix metalloproteinase-9 expression in bladder washes from bladder cancer patients predicts pathological stage and grade.  Clin Cancer Res. 1998;  4 (12) 3011-3016
    PubMedGoogle Scholar
  • 131 Kanayama H, Yokota K, Kurokawa Y, Murakami Y, Nishitani M, Kagawa S. Prognostic values of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 expression in bladder cancer.  Cancer. 1998;  82 (7) 1359-1366
    CrossrefPubMedGoogle Scholar
  • 132 Gohji K, Fujimoto N, Ohkawa J, Fujii A, Nakajima M. Imbalance between serum matrix metalloproteinase-2 and its inhibitor as a predictor of recurrence of urothelial cancer.  Br J Cancer. 1998;  77 (4) 650-655
    PubMedGoogle Scholar
  • 133 Kitagawa Y, Kunimi K, Ito H, Sato H, Uchibayashi T, Okada Y, Seiki M, Namiki M. Expression and tissue localization of membrane-types 1, 2 and 3 matrix metalloproteinases in human urothelial carcinomas.  J Urol. 1998;  160 (4) 1540-1545
    PubMedGoogle Scholar
  • 134 Sauter G, Haley J, Chew K, Kerschmann R. Epidermal growth-factor-receptor expression is associated with rapid tumor proliferation in bladder cancer.  Int J Cancer. 1994;  15 (57) 508-514
    PubMedGoogle Scholar
  • 135 Messing E M. Clinical implications of the expression of epidermal growth factor receptors in human transitional cell carcinoma.  Cancer Res. 1990;  50 (8) 2530-2537
    PubMedGoogle Scholar
  • 136 Neal D E, Marsh C, Bennett M K, Abel P D, Hall R R, Sainsbury J R, Harris A L. Epidermal growth factor receptors in human bladder cancer: comparison of invasive and superficial tumours.  Lancet. 1985;  1 366-368
    PubMedGoogle Scholar
  • 137 Ravery V, Grignon D, Angulo J, Pontes E, Montie J, Crissman J, Chopin D. Evaluation of epidermal growth factor receptor, transforming growth factor alpha, epidermal growth factor and c-erbB2 in the progression of invasive bladder cancer.  Urol Res. 1997;  25 9-17
    CrossrefPubMedGoogle Scholar
  • 138 Sriplakich S, Jahnson S, Karlsson M G. Epidermal growth factor receptor expression: predictive value for the outcome after cystectomy for bladder cancer.  BJU Int. 1999;  83 (4) 498-503
    PubMedGoogle Scholar
  • 139 Messing E M, Murphy-Brooks N. Recovery of epidermal growth factor in voided urine of patients with bladder cancer.  Urology. 1994;  44 502-505
    CrossrefPubMedGoogle Scholar
  • 140 Chopin D K, Caruelle J P, Colombel M, Palcy S, Ravery V, Caruelle D, Abbou C C, Barritault D. Increased immunodetection of acidic fibroblast growth factor in bladder cancer, detectable in urine.  J Urol. 1993;  150 1126-1130
    PubMedGoogle Scholar
  • 141 Gazzaniga P, Gandini O, Gradilone A, Silvestri I, Giuliani L, Magnanti M, Gallucci M, Saccani G. Detection of basic fibroblast growth factor mRNA in urinary bladder cancer: correlation with local relapses.  Int J Oncol. 1999;  14 (6) 1123-1127
    PubMedGoogle Scholar
  • 142 Edgren M, Lennernas B, Larsson A, Nilsson S. Serum concentrations of VEGF and b-FGF in renal cell, prostate and urinary bladder carcinomas.  Anticanc Res. 1999;  19 (1B) 869-873
    PubMedGoogle Scholar
  • 143 Eder I E, Stenzl A, Hobisch A, Cronauer M V, Bartsch G, Klocker H. Transforming growth factors beta-1 and beta-2 in serum and urine from patients with bladder cancer.  J Urol. 1996;  156 953-957
    PubMedGoogle Scholar
  • 144 Izadifar V, de Boer W I, Muscatelli-Groux B, Maille P, van der Kwast T H, Chopin D. Expression of transforming growth factor beta 1 and its receptors in normal human urothelium and human transitional cell carcinomas.  Hum Pathol. 1999;  30 (4) 372-377
    CrossrefPubMedGoogle Scholar
  • 145 Tokunaga H, Lee D H, Kim I Y, Wheeler T M, Lerner S P. Decreased expression of transforming growth factor beta receptor type I is associated with poor prognosis in bladder transitional cell carcinoma patients.  Clin Cancer Res. 1999;  5 (9) 2520-2525
    PubMedGoogle Scholar
  • 146 Thogersen V B, Jorgensen P E, Sorensen B S, Bross P, Orntoft T, Wolf H, Nexo E. Expression of transforming growth factor alpha and epidermal growth factor receptor in human bladder cancer.  Scand J Clin Lab Invest. 1999;  59 (4) 267-277
    PubMedGoogle Scholar
  • 147 Crew J P, O'Brian T, Bicknell R, Fuggle S, Cranston D, Harris A L. Urinary vascular endothelial growth factor and its correlation with bladder cancer recurrence rates.  J Urol. 1999;  161 (3) 799-804
    PubMedGoogle Scholar
  • 148 Ogura Y, Sato K, Kato T, Saito K, Enomoto K. Immunohistochemical analysis of expression of angiogenic factors and tumor angiogenesis in superficial bladder cancer.  Nippon Hinyokika Gakkai Zasshi. 1998;  89 529-537
    PubMedGoogle Scholar
  • 149 Basu A, Haldar S. The relationship between BcI2, Bax and p53: consequences for cell cycle progression and cell death.  Mol Hum Reprod. 1998;  4 (12) 1099-1109
    CrossrefPubMedGoogle Scholar
  • 150 Gazzangia P, Gradilone A, Vercillo R, Gandini O, Silvestri I. Bcl-2/bax mRNA expression ratio as prognostic factor in low grade urinary bladder cancer.  Int J Cancer. 1996;  69 100-104
    CrossrefPubMedGoogle Scholar
  • 151 Plastiras D, Moutzouris G, Barbatis C, Presvelos V, Theodorou C, Petrakos M. Can p53 nuclear over-expression, BcI-2 accumulation and PCNA status be of prognostic significance in high-risk superficial and invasive bladder tumours.  Eur J Surg Oncol. 1999;  25 (1) 61-65
    CrossrefPubMedGoogle Scholar
  • 152 Ju S T, Matsui K, Ozdemirli M. Molecular and cellular mechanisms regulating T and B cell apoptosis through Fas/FasL interaction.  Int Rev Immunol. 1999;  18 (5 - 6) 485-513
    PubMedGoogle Scholar
  • 153 Lee S H, Lee J Y, Park W S, Kim S Y, Jang J J, Yoo N J. Transitional cell carcinoma expresses high levels of Fas ligand in vivo.  BJU Int. 1999;  83 (6) 698-702
    CrossrefPubMedGoogle Scholar
  • 154 Mizutani Y, Yoshida O, Bonavida B. Prognostic significance of soluble Fas in the serum of patients with bladder cancer.  J Urol. 1998;  160 (2) 571-576
    PubMedGoogle Scholar
  • 155 Ambrosini G, Adida C, Altieri D C. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma.  Nat Med. 1997;  3 (8) 917-921
    CrossrefPubMedGoogle Scholar
  • 156 Swana H S, Grossman D, Anthony J N, Weiss R M, Altieri D C. Tumor content of the antiapoptosis molecule survivin and recurrence of bladder cancer.  N Engl J Med. 1999;  341 (6) 452-453
    CrossrefPubMedGoogle Scholar
  • 157 van der Poel H G. Markers for recurrence of superficial bladder cancer: what is valid.  Curr Opin Urol. 1999;  9 (5) 401-406
    CrossrefPubMedGoogle Scholar
  • 158 Miyake H, Hara I, Gohji K, Yamanaka K, Arakawa S, Kamidono S. Urinary cytology and competitive reverse transcriptase-polymerase chain reaction analysis of a specific CD44 variant to detect and monitor bladder cancer.  J Urol. 1998;  160 (6 Pt 1) 2004-2008
    PubMedGoogle Scholar
  • 159 Lipponen P, Aaltoma S, Kosma V M, Ala-Opas M, Eskelinen M. Expression of CD44 standard and variant-v6 proteins in transitional cell bladder tumours and their relation to prognosis during a long-term follow-up.  J Pathol. 1998;  186 (2) 157-164
    PubMedGoogle Scholar
  • 160 Alizadeh A A, Eisen M B, Davis R E, Ma C, Lossos I S, Rosenwald A, Boldrick J C, Sabet H. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling.  Nature. 2000;  403 (6769) 503-511
    CrossrefPubMedGoogle Scholar
  • 161 van der Poehl H G, van Balken M R, Schamhart D H. et al . Bladder wash cytology, quantitative cytology and the quantitative BTA test in patients with superficial bladder cancer.  Urology. 1998;  51 44-50
    CrossrefPubMedGoogle Scholar
  • 162 Thomas L, Leyh H, Marberger M. et al . Multicenter trial of the quantitative BTA TRAK assay in the detection of bladder cancer.  Clin Chem. 1999;  45 472-477
    PubMedGoogle Scholar
  • 163 Abbate I, D'Introno A, Cardo G. et al . Comparison of nuclear matrix protein 22 and bladder tumor antigen in urine of patients with bladder cancer.  Anticancer Res. 1998;  18 3803-3805
    PubMedGoogle Scholar
  • 164 Miyanaga N, Akaza H, Ishikawa S, Ohtani M, Noguchi R, Kawai K, Koiso K, Kobayashi M. Clinical evaluation of nuclear matrix protein 22 (NMP22) in urine as a novel marker for urothelial cancer.  Eur Urol. 1997;  31 (2) 163-168
    PubMedGoogle Scholar
  • 165 Sánchez-Carbayo M, Espasa A, Chinchilla V, Herrero E, Megias J, Mira A, Soria F. New electrochemiluminescent immunoassay for the determination of CYFRA 21-1: analytical evaluation and clinical diagnostic performance in urine samples of patients with bladder cancer.  Clin Chem. 1999;  45 (11) 1944-1953
    PubMedGoogle Scholar

Prof. Dr. med A Böhle

Klinik für Urologie Medizinische Universität zu Lübeck

Ratzeburger Allee 160 23538 Lübeck

      >